Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors (NCT05784688)

🧪 Interventions in This Study

• TU2218 + KEYTRUDA® (Pembrolizumab) (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (11 Sites)

• NEXT Oncology — San Antonio, Texas
• Hope Cancer Center — Tyler, Texas
• Medical Oncology — Spokane, Washington
• CHA University Bundang Medical Center — Seongnam,
• Seoul National University Bundang Hospital — Seongnam,
• Asan Medical Center — Seoul,
• Samsung Medical Center — Seoul,
• Seoul National University Hospital — Seoul,
• Severance Hospital — Seoul,
• The Catholic University of Korea Seoul St. Mary Hospital — Seoul,
• The Catholic University of Korea St. Vincent's Hospital — Suwon,

📞 Contact the Study Coordinator

Phone: 82-31-600-1500

Email: nce401_tu2218@tiumbio.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Solid Tumor

• A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors — Houston, Texas
• A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor Cancer — Middletown, New Jersey
• A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer — Basking Ridge, New Jersey
• Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors — Chicago, Illinois
• A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors — New York, New York
• Concurrent Azeliragon With Craniospinal Irradiation — New York, New York

Explore by condition: All Solid Tumor clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.